株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

ワクチンの世界市場:2021年までの予測 - 肺炎球菌・インフルエンザ・HPV・肝炎・ロタウイルス・DTP・ポリオ・MMR

Vaccine Market by Technology (Live, Conjugate, Toxoid, Recombinant), Disease (Influenza, DTaP, HPV, Hepatitis, Rotavirus, TT, Polio, MMR, Varicella, Dengue, TB, Rabies), Route (IM, SC, ID, Oral), End User (Pediatric, Adult) & Type - Forecast to 2022

発行 MarketsandMarkets 商品コード 278597
出版日 ページ情報 英文 206 Pages
即納可能
価格
本日の銀行送金レート: 1USD=110.15円で換算しております。
Back to Top
ワクチンの世界市場:2021年までの予測 - 肺炎球菌・インフルエンザ・HPV・肝炎・ロタウイルス・DTP・ポリオ・MMR Vaccine Market by Technology (Live, Conjugate, Toxoid, Recombinant), Disease (Influenza, DTaP, HPV, Hepatitis, Rotavirus, TT, Polio, MMR, Varicella, Dengue, TB, Rabies), Route (IM, SC, ID, Oral), End User (Pediatric, Adult) & Type - Forecast to 2022
出版日: 2017年08月14日 ページ情報: 英文 206 Pages
概要

2016年の322億4000万米ドルから8.3%のCAGR (複合年間成長率) で成長し、2019年までに480億3000万米ドルに達すると予測されています。同市場の主要な成長促進因子は、各種疾患の患者数の多さや、政府・民間からのワクチン開発への巨額の援助、予防接種計画への関心増加などがあります。更に、研究開発 (R&D) 費用の増額や、民間企業による新規ワクチン開発も、市場の更なる成長に貢献しています。

当レポートでは、ワクチンの世界市場について調査し、市場の概要、技術・種類・適応症・エンドユーザーおよび地域別の市場分析と予測を提供しており、競合情勢や主要企業のプロファイルをまとめ、お届け致します。

第1章 イントロダクション

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 重要考察

第5章 ワクチンの世界市場:概要

  • イントロダクション
  • 市場区分
  • 市場ダイナミクス
    • 促進要因
      • 各種疾患の有病者数の多さ
      • 政府・民間からのワクチン開発への資金提供
      • 各企業の投資増額
      • 予防接種プログラムに対する政府の関心
    • 抑制要因
      • 巨額の資本投資
      • 厳格な規制
    • 市場機会
      • 新興国市場での急速な成長の見通し
      • 治療用ワクチン
      • アジュバントワクチン
    • 課題
      • ワクチンの入手可能性の低さ
      • ワクチンの価格設定
    • 目下の課題
      • ワクチンの失敗事例
  • 投資分析
  • 世界各地の規制情勢
  • 特許分析
  • 主なパイプライン製品

第6章 ワクチンの世界市場:技術別

  • イントロダクション
  • 結合型ワクチン
  • 不活性化・サブユニットワクチン
  • 弱毒化生ワクチン
  • トキソイドワクチン
  • 組み換えワクチン

第7章 ワクチンの世界市場:種類別

  • イントロダクション
  • 単価ワクチン
  • 多価ワクチン

第8章 ワクチンの世界市場:適応症別

  • イントロダクション
  • 肺炎球菌性疾患
  • DTP (三種混合ワクチン)
  • インフルエンザ
  • ヒトパピローマウイルス
  • 髄膜炎菌性疾患
  • ポリオ (小児まひ)
  • ロタウィルス
  • 肝炎
  • MMR (新三種混合ワクチン)
  • 水痘
  • その他

第9章 ワクチンの世界市場:エンドユーザー別

  • イントロダクション
  • 小児
  • 成人

第10章 ワクチンの世界市場:地域別

  • イントロダクション
  • 北米 (米国、カナダ)
  • 欧州 (ドイツ、英国、フランス、イタリア、スペインなど)
  • アジア (日本、中国、インドなど)
  • 他の国々 (RoW)

第11章 競合情勢

  • 概要
  • 市場シェア分析
  • 競合状況・動向
    • 協定・事業提携・事業協力
    • 規制の承認
    • 企業合併
    • 事業拡張
    • その他の動き

第12章 企業プロファイル

  • イントロダクション
  • PFIZER, INC.
  • GLAXOSMITHKLINE, PLC.
  • MERCK & CO., INC.
  • SANOFI PASTEUR
  • CSL LIMITED
  • EMERGENT BIOSOLUTIONS, INC.
  • JOHNSON & JOHNSON
  • MEDIMMUNE, LLC. (ASTRAZENECAの子会社)
  • アステラス製薬
  • SERUM INSTITUTE OF INDIA

第13章 付録

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: BT 3113

"Global vaccines market projected to grow at a CAGR of 7.5%"

The vaccines market is expected to reach USD 49.27 billion by 2022 from USD 34.30 billion in 2017, at a CAGR of 7.5%. Rising prevalence of diseases, increasing government and nongovernment funding for vaccine development, and increasing investments by companies are driving the growth of the vaccines market. On the other hand, market growth may be hindered due to the high cost of vaccine development and product recalls.

"Conjugate vaccines are expected to dominate the market during the forecast period."

By technology, the vaccines market is segmented into conjugate vaccines, inactivated and subunit vaccines, live attenuated vaccines, recombinant vaccines, and toxoid vaccines. The conjugate segment is expected to hold the largest share of the market in 2017 and is also projected to register the highest CAGR during the forecast period. Rising prevalence of diseases and increasing government investments are the key factors driving the growth of this segment.

"Monovalent vaccines segment expected to hold the largest share of the market in 2017."

Based on type, the vaccines market is segmented into monovalent vaccines and multivalent vaccines. The monovalent segment is expected to dominate this market with the largest share due to increasing investments by companies to develop new vaccines.

"Pneumococcal disease segment is expected to witness high growth during the forecast period"

Based on the disease indication, the vaccines market is segmented into pneumococcal disease, influenza, DTP, hepatitis, human papillomavirus (HPV), rotavirus, meningococcal disease, MMR (measles, mumps, and rubella), varicella, polio, dengue, and other disease indications. The pneumococcal segment is expected to account for the largest share and is projected to register the highest rate during the forecast period. The growth in this segment can primarily be attributed to increasing government investments in pneumococcal vaccination programs and high incidence of pneumococcal disease.

"Asia to witness high growth during the forecast period"

In 2017, North America is expected to account for the largest share of the market followed by Europe. However, Asia is expected to register the highest CAGR during the forecast period. The high growth in this segment is attributed to the increasing investments by companies in India and China, rising disposable income, growing number of awareness programs and symposia, and growing venture capital investments.

The primary interviews conducted for this report can be categorized as follows:

  • By Company Type: Tier 1 - 36%; Tier 2 - 41%; Tier 3 - 23%.
  • By Designation (Supply Side): C-level - 25%; D-level - 29%; Others - 46%.
  • By Designation (Demand Side): General Physicians - 38%; Purchase Managers - 29%; Medical Researchers - 33%.
  • By Region: North America - 40%; Europe - 20%; Asia - 33%; RoW - 7%.

List of companies profiled in the report

  • GlaxoSmithKline plc
  • Pfizer, Inc.
  • Merck & Co., Inc.
  • Sanofi Pasteur SA
  • CSL Limited
  • Emergent BioSolutions, Inc.
  • Johnson & Johnson
  • MedImmune, LLC
  • Astellas Pharma Inc.
  • Serum Institute of India
  • Bavarian Nordic
  • Mitsubishi Tanabe Pharma Corporation
  • Daiichi Sankyo Company, Limited
  • Protein Science Corporation
  • Panacea Biotec

Research Coverage:

The report provides an overview of the vaccines market. It aims at estimating the market size and future growth potential of this market across different segments such as technology, type, disease indication, route of administration, end user, and region. Furthermore, the report also includes an in-depth competitive analysis of the key players in the market along with their company profiles, recent developments, and key market strategies.

Key Benefits of Buying the Report:

The report will help the market leaders/new entrants in this market by providing them with the closest approximations of revenues for the overall vaccines market and its subsegments. This report will help stakeholders to understand the competitive landscape better and gain insights to position their businesses and help companies make suitable go-to-market strategies. The report also helps stakeholders understand the pulse of the market and provide them with information regarding key market drivers and opportunities.

TABLE OF CONTENTS

1 INTRODUCTION 17

  • 1.1 OBJECTIVES OF THE STUDY 17
  • 1.2 MARKET DEFINITION 17
  • 1.3 MARKET SCOPE 18
    • 1.3.1 MARKET COVERED 18
    • 1.3.2 YEARS CONSIDERED FOR THE STUDY 19
  • 1.4 CURRENCY 19
  • 1.5 LIMITATION 19
  • 1.6 MARKET STAKEHOLDERS 19

2 RESEARCH METHODOLOGY 21

  • 2.1 SECONDARY DATA 22
  • 2.2 PRIMARY DATA 23
  • 2.3 KEY INDUSTRY INSIGHTS 24
  • 2.4 MARKET SIZE ESTIMATION 25
  • 2.5 MARKET BREAKDOWN AND DATA TRIANGULATION 28
  • 2.6 MARKET SHARE ESTIMATION 29
  • 2.7 ASSUMPTIONS FOR THE STUDY 29

3 EXECUTIVE SUMMARY 30

4 PREMIUM INSIGHTS 34

  • 4.1 OVERVIEW OF THE VACCINES MARKET 34
  • 4.2 VACCINES MARKET, BY TYPE, 2017-2022 35
  • 4.3 VACCINES MARKET, BY END USER, 2017 VS. 2022 (USD BILLION) 35
  • 4.4 GEOGRAPHIC ANALYSIS: VACCINES MARKET, BY TECHNOLOGY 36
  • 4.5 VACCINES MARKET, BY ROUTE OF ADMINISTRATION, 2017 VS. 2022 (USD BILLION) 37
  • 4.6 GEOGRAPHICAL SNAPSHOT OF THE VACCINES MARKET 37

5 MARKET OVERVIEW 38

  • 5.1 INTRODUCTION 39
  • 5.2 MARKET DYNAMICS 39
    • 5.2.1 DRIVERS 40
      • 5.2.1.1 High prevalence of infectious diseases 40
      • 5.2.1.2 Rising focus on immunization programs 40
      • 5.2.1.3 Growing government support for vaccine development 41
      • 5.2.1.4 Increasing company investments into vaccine R&D 42
    • 5.2.2 RESTRAINTS 43
      • 5.2.2.1 High cost of vaccine development 43
      • 5.2.2.2 Product Recalls 43
    • 5.2.3 OPPORTUNITIES 44
      • 5.2.3.1 High growth prospects in emerging markets 44
      • 5.2.3.2 Focus on therapeutic vaccines 44
      • 5.2.3.3 Use of adjuvants in vaccines 44
    • 5.2.4 CHALLENGES 45
      • 5.2.4.1 Inadequate access to vaccines 45
    • 5.2.5 BURNING ISSUES 45
      • 5.2.5.1 Vaccine pricing 45

6 INDUSTRY INSIGHTS 46

  • 6.1 INVESTMENT ANALYSIS 46
  • 6.2 REGULATORY LANDSCAPE 48
    • 6.2.1 NORTH AMERICA 49
    • 6.2.2 EUROPE 50
    • 6.2.3 ASIA 50
    • 6.2.4 ROW 51
  • 6.3 KEY PIPELINE PRODUCTS 52
  • 6.4 NEW VACCINE OPPORTUNITIES 53
    • 6.4.1 HIV 53
      • 6.4.1.1 HIV vaccine: Product pipeline 53
      • 6.4.1.2 HIV vaccine: Public-private initiatives 54
      • 6.4.1.3 HIV vaccine: Funding 54
    • 6.4.2 MALARIA 56
      • 6.4.2.1 Malaria vaccine: Product pipeline 56
      • 6.4.2.2 Malaria vaccine: Public-private initiatives 57
    • 6.4.3 ZIKA 57
      • 6.4.3.1 Zika vaccine: Product pipeline 57
      • 6.4.3.2 Zika vaccine: Public-private initiatives 57
      • 6.4.3.3 Zika vaccine: Funding 58
    • 6.4.4 EBOLA 58
      • 6.4.4.1 Ebola vaccine: Product pipeline 58
      • 6.4.4.2 Ebola vaccine: Public-private initiatives 59
      • 6.4.4.3 Ebola vaccine: Funding 59

7 VACCINES MARKET, BY TECHNOLOGY 60

  • 7.1 INTRODUCTION 61
  • 7.2 CONJUGATE VACCINES 62
  • 7.3 INACTIVATED AND SUBUNIT VACCINES 63
  • 7.4 LIVE ATTENUATED VACCINES 65
  • 7.5 RECOMBINANT VACCINES 66
  • 7.6 TOXOID VACCINES 67

8 VACCINES MARKET, BY TYPE 68

  • 8.1 INTRODUCTION 69
  • 8.2 MONOVALENT VACCINES 70
  • 8.3 MULTIVALENT VACCINES 71

9 VACCINES MARKET, BY DISEASE INDICATION 73

  • 9.1 INTRODUCTION 74
  • 9.2 PNEUMOCOCCAL DISEASE 75
  • 9.3 DTP 76
  • 9.4 INFLUENZA 77
  • 9.5 HUMAN PAPILLOMA VIRUS 78
  • 9.6 MENINGOCOCCAL DISEASE 80
  • 9.7 POLIO 81
  • 9.8 ROTAVIRUS 83
  • 9.9 HEPATITIS 84
  • 9.10 MMR 85
  • 9.11 VARICELLA 86
  • 9.12 DENGUE 87
  • 9.13 OTHER DISEASE INDICATIONS 88

10 VACCINES MARKET, BY ROUTE OF ADMINISTRATION 90

  • 10.1 INTRODUCTION 91
  • 10.2 INTRAMUSCULAR AND SUBCUTANEOUS ADMINISTRATION 92
  • 10.3 ORAL ADMINISTRATION 93
  • 10.4 OTHER ROUTES OF ADMINISTRATION 94

11 VACCINES MARKET, BY END USER 95

  • 11.1 INTRODUCTION 96
  • 11.2 PEDIATRICS 97
  • 11.3 ADULTS 98

12 VACCINES MARKET, BY REGION 100

  • 12.1 INTRODUCTION 101
  • 12.2 NORTH AMERICA 101
    • 12.2.1 U.S. 105
    • 12.2.2 CANADA 106
  • 12.3 EUROPE 108
    • 12.3.1 GERMANY 112
    • 12.3.2 U.K. 113
    • 12.3.3 FRANCE 114
    • 12.3.4 ITALY 115
    • 12.3.5 SPAIN 116
    • 12.3.6 REST OF EUROPE (ROE) 117
  • 12.4 ASIA 118
    • 12.4.1 JAPAN 122
    • 12.4.2 CHINA 123
    • 12.4.3 INDIA 124
    • 12.4.4 REST OF ASIA (ROA) 125
  • 12.5 REST OF THE WORLD (ROW) 126

13 COMPETITIVE LANDSCAPE 130

  • 13.1 INTRODUCTION 130
  • 13.2 MARKET SHARE ANALYSIS 130
  • 13.3 COMPETITIVE LEADERSHIP MAPPING 132
    • 13.3.1 VISIONARY LEADERS 132
    • 13.3.2 INNOVATORS 132
    • 13.3.3 DYNAMIC DIFFERENTIATORS 132
    • 13.3.4 EMERGING COMPANIES 132
  • 13.4 STRENGTH OF PRODUCT PORTFOLIO (FOR 25 PLAYERS) 134
  • 13.5 BUSINESS STRATEGY EXCELLENCE (FOR 25 PLAYERS) 135

Top 25 companies analyzed for this studies are - Pfizer, Inc., GlaxoSmithKline plc., Merck & Co., Inc., Sanofi Pasteur SA, CSL Limited, Emergent BioSolutions, Inc., Johnson & Johnson, MedImmune, LLC, Astellas Pharma Inc., Serum Institute of India, Bavarian Nordic, Mitsubishi Tanabe Pharma Corporation, Protein Science Corporation, Daiichi Sankyo Company, Limited, Abbott Laboratories, Panacea Biotec, PaxVax, Inc., Zydus Cadila, Green Cross Corporation, Valneva SE, Indian Immunologicals Limited, Incepta Vaccine Ltd., Sinovac Biotech Ltd., VBI Vaccines Inc., PT Bio Farma (Persero)

14 COMPANY PROFILES 136

(Overview, Products Offered, Product Offering Scorecard, Business Strategy Scorecard, Recent Developments)*

  • 14.1 PFIZER, INC. 136
  • 14.2 GLAXOSMITHKLINE PLC. 141
  • 14.3 MERCK & CO., INC. 146
  • 14.4 SANOFI PASTEUR SA 150
  • 14.5 CSL LIMITED 155
  • 14.6 EMERGENT BIOSOLUTIONS, INC. 159
  • 14.7 JOHNSON & JOHNSON 164
  • 14.8 MEDIMMUNE, LLC (A SUBSIDIARY OF ASTRAZENECA) 168
  • 14.9 ASTELLAS PHARMA, INC. 171
  • 14.10 SERUM INSTITUTE OF INDIA 174
  • 14.11 BAVARIAN NORDIC 177
  • 14.12 MITSUBISHI TANABE PHARMA CORPORATION 182
  • 14.13 DAIICHI SANKYO COMPANY, LIMITED 185
  • 14.14 PROTEIN SCIENCES CORPORATION 189
  • 14.15 PANACEA BIOTEC 193

Details on MarketsandMarkets view, Overview, Products Offered, Product Offering Scorecard, Business Strategy Scorecard, and Recent Developments might not be captured in case of unlisted companies.

15 APPENDIX 196

  • 15.1 INSIGHTS OF INDUSTRY EXPERTS 196
  • 15.2 DISCUSSION GUIDE 197
  • 15.3 KNOWLEDGE STORE: MARKETSANDMARKETS' SUBSCRIPTION PORTAL 200
  • 15.4 INTRODUCING RT: REAL-TIME MARKET INTELLIGENCE 202
  • 15.5 AVAILABLE CUSTOMIZATIONS 202
  • 15.6 RELATED REPORTS 203
  • 15.7 AUTHOR DETAILS 204

LIST OF TABLES

  • TABLE 1 INCIDENCE OF DISEASES, 2015 40
  • TABLE 2 NIH FUNDING FOR VACCINE RESEARCH, 2012-2017 (USD MILLION) 42
  • TABLE 3 IMMUNIZATION COVERAGE, BY DISEASE, 2014 VS 2015 45
  • TABLE 4 REGULATORY AUTHORITIES IN EUROPE 50
  • TABLE 5 REGULATORY AUTHORITIES IN ASIA 51
  • TABLE 6 KEY PIPELINE VACCINES 52
  • TABLE 7 ESTIMATED INVESTMENT IN HIV VACCINES, BY INVESTOR (2015-2016) 55
  • TABLE 8 EBOLA PROJECTS FUNDED BY EUROPEAN COMMISSION (2014-2020) 59
  • TABLE 9 VACCINES MARKET, BY TECHNOLOGY, 2015-2022 (USD MILLION) 61
  • TABLE 10 COST OF MENINGOCOCCAL CONJUGATE VACCINES 62
  • TABLE 11 CONJUGATE VACCINES MARKET, BY REGION, 2015-2022 (USD MILLION) 62
  • TABLE 12 EXAMPLES OF INACTIVATED AND SUBUNIT VACCINES 64
  • TABLE 13 INACTIVATED AND SUBUNIT VACCINES MARKET, BY REGION, 2015-2022 (USD MILLION) 64
  • TABLE 14 LIVE ATTENUATED VACCINES MARKET, BY REGION, 2015-2022 (USD MILLION) 65
  • TABLE 15 EXAMPLES OF RECOMBINANT VACCINES 66
  • TABLE 16 RECOMBINANT VACCINES MARKET, BY REGION, 2015-2022 (USD MILLION) 66
  • TABLE 17 TOXOID VACCINES MARKET, BY REGION, 2015-2022 (USD MILLION) 67
  • TABLE 18 VACCINES MARKET, BY TYPE, 2015-2022 (USD MILLION) 69
  • TABLE 19 MONOVALENT VACCINES MARKET, BY REGION, 2015-2022 (USD MILLION) 70
  • TABLE 20 EXAMPLES OF NOTABLE MULTIVALENT VACCINES AVAILABLE IN THE MARKET 71
  • TABLE 21 MULTIVALENT VACCINES MARKET, BY REGION, 2015-2022 (USD MILLION) 72
  • TABLE 22 VACCINES MARKET, BY DISEASE INDICATION, 2015-2022 (USD MILLION) 74
  • TABLE 23 LIST OF COMMERCIALLY AVAILABLE PNEUMOCOCCAL VACCINES IN THE MARKET 75
  • TABLE 24 VACCINES MARKET FOR PNEUMOCOCCAL DISEASE, BY REGION, 2015-2022 (USD MILLION) 75
  • TABLE 25 LIST OF COMMERCIALLY AVAILABLE DTP VACCINES IN THE MARKET 76
  • TABLE 26 VACCINES MARKET FOR DTP, BY REGION, 2015-2022 (USD MILLION) 77
  • TABLE 27 LIST OF COMMERCIALLY AVAILABLE INFLUENZA VACCINES IN THE MARKET 78
  • TABLE 28 VACCINES MARKET FOR INFLUENZA, BY REGION, 2015-2022 (USD MILLION) 78
  • TABLE 29 LIST OF COMMERCIALLY AVAILABLE HPV VACCINES IN THE MARKET 79
  • TABLE 30 VACCINES MARKET FOR HPV, BY REGION, 2015-2022 (USD MILLION) 79
  • TABLE 31 LIST OF COMMERCIALLY AVAILABLE HPV VACCINES IN THE MARKET 80
  • TABLE 32 VACCINES MARKET FOR MENINGOCOCCAL DISEASE, BY REGION, 2015-2022 (USD MILLION) 81
  • TABLE 33 LIST OF COMMERCIALLY AVAILABLE POLIO VACCINES IN THE MARKET 82
  • TABLE 34 VACCINES MARKET FOR POLIO, BY REGION, 2015-2022 (USD MILLION) 82
  • TABLE 35 LIST OF COMMERCIALLY AVAILABLE ROTAVIRUS VACCINES IN THE MARKET 83
  • TABLE 36 VACCINES MARKET FOR ROTAVIRUS, BY REGION, 2015-2022 (USD MILLION) 83
  • TABLE 37 LIST OF COMMERCIALLY AVAILABLE HEPATITIS VACCINES IN THE MARKET 84
  • TABLE 38 VACCINES MARKET FOR HEPATITIS, BY REGION, 2015-2022 (USD MILLION) 84
  • TABLE 39 LIST OF COMMERCIALLY AVAILABLE MMR VACCINES IN THE MARKET 85
  • TABLE 40 VACCINES MARKET FOR MMR, BY REGION, 2015-2022 (USD MILLION) 85
  • TABLE 41 LIST OF COMMERCIALLY AVAILABLE VARICELLA VACCINES IN THE MARKET 86
  • TABLE 42 VACCINES MARKET FOR VARICELLA, BY REGION, 2015-2022 (USD MILLION) 86
  • TABLE 43 LIST OF COMMERCIALLY AVAILABLE VACCINES FOR OTHER DISEASE INDICATIONS IN THE MARKET 88
  • TABLE 44 VACCINES MARKET FOR OTHER DISEASE INDICATIONS, BY REGION, 2015-2022 (USD MILLION) 89
  • TABLE 45 VACCINES MARKET, BY ROUTE OF ADMINISTRATION, 2015-2022 (USD MILLION) 91
  • TABLE 46 VACCINES MARKET FOR INTRAMUSCULAR AND SUBCUTANEOUS ADMINISTRATION, BY REGION, 2015-2022 (USD MILLION) 92
  • TABLE 47 VACCINES MARKET FOR ORAL ADMINISTRATION, BY REGION, 2015-2022 (USD MILLION) 93
  • TABLE 48 VACCINES MARKET FOR OTHER ROUTES OF ADMINISTRATION, BY REGION, 2015-2022 (USD MILLION) 94
  • TABLE 49 VACCINES MARKET SIZE, BY END USER, 2015-2022 (USD MILLION) 96
  • TABLE 50 PEDIATRIC VACCINES MARKET, BY REGION, 2015-2022 (USD MILLION) 97
  • TABLE 51 NORTH AMERICA: PEDIATRIC VACCINES MARKET, BY COUNTRY, 2015-2022 (USD MILLION) 98
  • TABLE 52 ADULT VACCINES MARKET, BY REGION, 2015-2022 (USD MILLION) 99
  • TABLE 53 NORTH AMERICA: ADULT VACCINES MARKET, BY COUNTRY, 2015-2022 (USD MILLION) 99
  • TABLE 54 VACCINES MARKET, BY REGION, 2015-2022 (USD MILLION) 101
  • TABLE 55 NORTH AMERICA: VACCINES MARKET, BY COUNTRY, 2015-2022 (USD MILLION) 103
  • TABLE 56 NORTH AMERICA: VACCINES MARKET, BY TECHNOLOGY, 2015-2022 (USD MILLION) 103
  • TABLE 57 NORTH AMERICA: VACCINES MARKET, BY TYPE, 2015-2022 (USD MILLION) 103
  • TABLE 58 NORTH AMERICA: VACCINES MARKET, BY DISEASE INDICATION, 2015-2022 (USD MILLION) 104
  • TABLE 59 NORTH AMERICA: VACCINES MARKET, BY ROUTE OF ADMINISTRATION, 2015-2022 (USD MILLION) 104
  • TABLE 60 NORTH AMERICA: VACCINES MARKET, BY END USER, 2015-2022 (USD MILLION) 105
  • TABLE 61 U.S.: VACCINES MARKET, BY TECHNOLOGY, 2015-2022 (USD MILLION) 106
  • TABLE 62 U.S.: VACCINES MARKET, BY END USER, 2015-2022 (USD MILLION) 106
  • TABLE 63 CANADA: VACCINES MARKET, BY TECHNOLOGY, 2015-2022 (USD MILLION) 107
  • TABLE 64 CANADA: VACCINES MARKET, BY END USER, 2015-2022 (USD MILLION) 107
  • TABLE 65 EUROPE: VACCINES MARKET, BY COUNTRY, 2015-2022 (USD MILLION) 110
  • TABLE 66 EUROPE: VACCINES MARKET, BY TECHNOLOGY, 2015-2022 (USD MILLION) 110
  • TABLE 67 EUROPE: VACCINES MARKET, BY TYPE, 2015-2022 (USD MILLION) 110
  • TABLE 68 EUROPE: VACCINES MARKET, BY DISEASE INDICATION, 2015-2022 (USD MILLION) 111
  • TABLE 69 EUROPE: VACCINES MARKET, BY ROUTE OF ADMINISTRATION, 2015-2022 (USD MILLION) 111
  • TABLE 70 EUROPE: VACCINES MARKET, BY END USER, 2015-2022 (USD MILLION) 112
  • TABLE 71 GERMANY: VACCINES MARKET, BY TECHNOLOGY, 2015-2022 (USD MILLION) 113
  • TABLE 72 U.K.: VACCINES MARKET, BY TECHNOLOGY, 2015-2022 (USD MILLION) 114
  • TABLE 73 FRANCE: VACCINES MARKET, BY TECHNOLOGY, 2015-2022 (USD MILLION) 115
  • TABLE 74 ITALY: VACCINES MARKET, BY TECHNOLOGY, 2015-2022 (USD MILLION) 115
  • TABLE 75 SPAIN: VACCINES MARKET, BY TECHNOLOGY, 2015-2022 (USD MILLION) 116
  • TABLE 76 ROE: VACCINES MARKET, BY TECHNOLOGY, 2015-2022 (USD MILLION) 117
  • TABLE 77 ASIA: HEALTH EXPENDITURE PER CAPITA, BY COUNTRY, 2000 & 2014 (USD) 118
  • TABLE 78 ASIA: VACCINES MARKET, BY COUNTRY, 2015-2022 (USD MILLION) 120
  • TABLE 79 ASIA: VACCINES MARKET, BY TECHNOLOGY, 2015-2022 (USD MILLION) 120
  • TABLE 80 ASIA: VACCINES MARKET, BY TYPE, 2015-2022 (USD MILLION) 120
  • TABLE 81 ASIA: VACCINES MARKET, BY DISEASE INDICATION, 2015-2022 (USD MILLION) 121
  • TABLE 82 ASIA: VACCINES MARKET, BY ROUTE OF ADMINISTRATION, 2015-2022 (USD MILLION) 121
  • TABLE 83 ASIA: VACCINES MARKET, BY END USER, 2015-2022 (USD MILLION) 122
  • TABLE 84 JAPAN: VACCINES MARKET, BY TECHNOLOGY, 2015-2022 (USD MILLION) 123
  • TABLE 85 CHINA: VACCINES MARKET, BY TECHNOLOGY, 2015-2022 (USD MILLION) 124
  • TABLE 86 INDIA: VACCINES MARKET, BY TECHNOLOGY, 2015-2022 (USD MILLION) 125
  • TABLE 87 ROA: VACCINES MARKET, BY TECHNOLOGY, 2015-2022 (USD MILLION) 125
  • TABLE 88 ROW: VACCINES MARKET, BY TECHNOLOGY, 2015-2022 (USD MILLION) 128
  • TABLE 89 ROW: VACCINES MARKET, BY TYPE, 2015-2022 (USD MILLION) 128
  • TABLE 90 ROW: VACCINES MARKET, BY DISEASE INDICATION, 2015-2022 (USD MILLION) 129
  • TABLE 91 ROW: VACCINES MARKET, BY ROUTE OF ADMINISTRATION, 2015-2022 (USD MILLION) 129
  • TABLE 92 ROW: VACCINES MARKET, BY END USER, 2015-2022 (USD MILLION) 129

LIST OF FIGURES

  • FIGURE 1 VACCINES MARKET SEGMENTATION 18
  • FIGURE 2 RESEARCH DESIGN 21
  • FIGURE 3 KEY DATA FROM SECONDARY SOURCES 22
  • FIGURE 4 KEY DATA FROM PRIMARY SOURCES 23
  • FIGURE 5 MARKET SIZE ESTIMATION: BOTTOM-UP APPROACH 25
  • FIGURE 6 MARKET SIZE ESTIMATION: TOP-DOWN APPROACH 26
  • FIGURE 7 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION 27
  • FIGURE 8 DATA TRIANGULATION METHODOLOGY 28
  • FIGURE 9 VACCINES MARKET, BY TECHNOLOGY, 2017-2022 30
  • FIGURE 10 VACCINES MARKET, BY TYPE, 2017 VS. 2022 (USD BILLION) 31
  • FIGURE 11 VACCINES MARKET, BY DISEASE INDICATION, 2017 VS. 2022 (USD BILLION) 31
  • FIGURE 12 VACCINES MARKET, BY ROUTE OF ADMINISTRATION, 2017 VS. 2022 (USD BILLION) 32
  • FIGURE 13 VACCINES MARKET, BY END USER, 2017 VS. 2022 (USD BILLION) 32
  • FIGURE 14 GEOGRAPHICAL SNAPSHOT OF THE VACCINES MARKET 33
  • FIGURE 15 HIGH PREVALENCE OF DISEASES AND RISING GOVERNMENT & NONGOVERNMENT FUNDING FOR VACCINE DEVELOPMENT-PRIMARY GROWTH DRIVERS FOR THE GLOBAL VACCINES MARKET 34
  • FIGURE 16 MONOVALENT VACCINES TO REGISTER THE HIGHEST GROWTH RATE IN THE FORECAST PERIOD 35
  • FIGURE 17 PEDIATRICS SEGMENT WILL CONTINUE TO DOMINATE THE VACCINES MARKET IN 2022 35
  • FIGURE 18 CONJUGATE VACCINES TO ACCOUNT FOR THE LARGEST SHARE OF THE VACCINES MARKET IN 2017 36
  • FIGURE 19 INTRAMUSCULAR AND SUBCUTANEOUS ADMINISTRATION SEGMENT TO WITNESS THE HIGHEST GROWTH RATE IN THE FORECAST PERIOD 37
  • FIGURE 20 U.S. TO DOMINATE THE VACCINES MARKET IN 2017 37
  • FIGURE 21 VACCINE MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES 39
  • FIGURE 22 MAJOR INVESTORS IN THE GLOBAL VACCINES MARKET 46
  • FIGURE 23 VACCINE FUNDING, BY INVESTOR, 2014 47
  • FIGURE 24 GAVI VACCINE FUNDING, BY TYPE OF INVESTOR, 2014 47
  • FIGURE 25 GAVI FORECAST VACCINE EXPENDITURE, BY DISEASE, 2016-2020 48
  • FIGURE 26 REGULATORY APPROVAL PROCESS FOR VACCINES 49
  • FIGURE 27 R&D FUNDING FOR HIV PREVENTIVE VACCINES, BY INVESTOR, 2014 55
  • FIGURE 28 CONJUGATE VACCINES SEGMENT TO DOMINATE THE VACCINE TECHNOLOGIES MARKET DURING THE FORECAST PERIOD 61
  • FIGURE 29 MONOVALENT VACCINES TO DOMINATE THE GLOBAL VACCINES MARKET IN 2017 69
  • FIGURE 30 PNEUMOCOCCAL DISEASE SEGMENT WILL CONTINUE TO DOMINATE THE VACCINES MARKET IN 2022 74
  • FIGURE 31 GLOBAL VACCINES MARKET FOR DENGUE, 2015-2022 (USD MILLION) 87
  • FIGURE 32 INTRAMUSCULAR AND SUBCUTANEOUS ADMINISTRATION SEGMENT WILL CONTINUE TO DOMINATE THE GLOBAL VACCINES MARKET IN 2022 91
  • FIGURE 33 PEDIATRICS END-USER SEGMENT TO DOMINATE THE GLOBAL VACCINES MARKET IN 2017 96
  • FIGURE 34 NORTH AMERICA: VACCINES MARKET SNAPSHOT, 2017 102
  • FIGURE 35 EUROPE: VACCINES MARKET SNAPSHOT, 2017 109
  • FIGURE 36 ASIA: VACCINES MARKET SNAPSHOT, 2017 119
  • FIGURE 37 ROW: VACCINES MARKET SNAPSHOT, 2017 127
  • FIGURE 38 VACCINES MARKET SHARE ANALYSIS, BY KEY PLAYER, 2016 130
  • FIGURE 39 VACCINES MARKET (GLOBAL) COMPETITIVE LEADERSHIP MAPPING, 2017 133
  • FIGURE 40 PFIZER, INC.: COMPANY SNAPSHOT 136
  • FIGURE 41 GLAXOSMITHKLINE PLC.: COMPANY SNAPSHOT 141
  • FIGURE 42 MERCK & CO., INC.: COMPANY SNAPSHOT 146
  • FIGURE 43 SANOFI PASTEUR SA: COMPANY SNAPSHOT 150
  • FIGURE 44 CSL LIMITED: COMPANY SNAPSHOT 155
  • FIGURE 45 EMERGENT BIOSOLUTIONS: COMPANY SNAPSHOT 159
  • FIGURE 46 JOHNSON & JOHNSON: COMPANY SNAPSHOT 164
  • FIGURE 47 ASTRAZENECA: COMPANY SNAPSHOT 168
  • FIGURE 48 ASTELLAS PHARMA, INC.: COMPANY SNAPSHOT 171
  • FIGURE 49 BAVARIAN NORDIC: COMPANY SNAPSHOT 177
  • FIGURE 50 MITSUBISHI TANABE PHARMA CORPORATION: COMPANY SNAPSHOT 182
  • FIGURE 51 DAIICHI SANKYO COMPANY, LIMITED: COMPANY SNAPSHOT 185
  • FIGURE 52 PANACEA BIOTEC: COMPANY SNAPSHOT (2016) 193
Back to Top